MedTrace Logo

Teneligliptin and Atorvastatin DDI Study

NCT03769870 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-05-30

No results posted yet for this study

Summary

A randomized, open-label, cross-over, multiple dosing study to evaluate drug-drug interaction between Teneligliptin and Atorvastatin in healthy male adults

Conditions

  • Diabete Mellitus

Interventions

DRUG

Teneligliptin 20mg/day

cross-over

DRUG

Atorvastatin 40mg/Day

cross-over

DRUG

Teneligliptin 20mg/day + Atorvastatin 40mg/day

cross-over

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-11
Primary Completion
2019-02-25
Completion
2019-02-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03769870 on ClinicalTrials.gov